Challenges in Delivery of Biopharmaceuticals; the Need for Advanced Delivery Systems

Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines

Volumn , Issue , 2009, Pages 1-8

  Nielsen, Hanne Mørck ^a   Jorgensen, Lene ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Challenges in delivery of biopharmaceuticals need for advanced delivery systems; Delivery system formulation for biopharmaceuticals and biopharmaceutical molecular structure and stability; Drug delivery technologies and excipients; Formulation ensuring targeted delivery to site of action; Maximization of delivery to target site successful delivery for local and systemic delivery; Overcoming challenges of biopharmaceutical inactivation by physical conformational changes; Overcoming delivery barriers; Peptides and protein drugs and particulate encapsulation; Traditional biopharmaceuticals of biological origin supplemented by therapeutics

Indexed keywords

EID: 84878614586     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470688397.ch1     Document Type: Chapter

References (38)

1. Tauzin, B. (2008) Biotechnology research continues to bolster arsenal against disease with 633 medicines in development. Medicines in Development, Biotechnology, http://www.phrma.org/files/Biotech%202008.pdf (accessed 7 July 2009).
2. Walsh, G. (2006) Biopharmaceutical benchmarks. Nat. Biotech., 24, 769-776.
3. Russell-Jones, D. (2009) Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol. Cell Endocrinol, 297, 137-140.
4. WIPO (2007) Patent Application WO/2007/126808, Pegylated factor VIII, http://www.wipo. int/pctdb/en/wo.jsp?WO=2007126808 (accessed 7 July 2009).
5. Healy, J.M., Lewis, S.D., Kurz, M. et al. (2004) Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res., 21, 2234-2246.
6. Frokjaer, S. and Otzen, D.E. (2005) Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov., 4, 298-306.
7. Egrie, J.C., Dwyer, E., Browne, J.K. et al. (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol., 31, 290-299.
8. Fattal, E. and Bochot, A. (2008) State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int. J. Pharm., 364, 237-248.
9. Elmen, J., Lindow, M., Schutz, S. et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature, 452, 896-469.
10. Morishita, M. and Peppas, N.A. (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today, 11, 905-910.
11. Almeida, A.J. and Souto, E. (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Del. Rev., 59, 478-490.
12. Lai, W.-F. and Lin, M.C.-M. (2009) Nucleic acid delivery with chitosan and its derivatives. J. Control. Release, 134, 158-168.
13. Howard, K.A., Li, X.W., Somavarapu, S. et al. (2004) Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim. Biophys. Acta (BBA), 1674, 149-157.
14. Svenson, S. and Tomalia, D.A. (2005) Dendrimers: a Versatile Targeting Platform: dendrimers in biomedical applications-reflections on the field. Adv. Drug Del. Rev., 57, 2106-2129.
15. Wasungu, L. and Hoekstra, D. (2006) Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release, 116, 255-264.
16. Cun, D., Boye Jensen, L., M ø rck Nielsen, H. et al. (2008) Polymeric nanocarriers for siRNA delivery: challenges and future prospects. J. Biomed. Nanotech., 4, 1-18.
17. Ye, Q., Asherman, J., Stevenson, M. et al. (2000) DepoFoam(TM) technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Release, 64, 155-166.
18. Howell, S.B. (2001) Clinical application of a novel sustained-release injectable drug delivery system: Depofoam ™ technology. Cancer J., 7, 219-227.
19. Khafagy, E.-S., Morishita, M., Onuki, Y. and Takayama, K. (2007) Current challenges in non-invasive insulin delivery systems: a comparative review. Adv. Drug Del. Rev., 59, 1521-1546.
20. Johnson, P.H., Frank, D. and Costantino, H.R. (2008) Discovery of tight junction modulators: significance for drug development and delivery. Drug Discov. Today, 13, 261-267.
21. Khafagy, E.S., Morishita, M., Isowa, K. et al. (2009) Effect of cell-penetrating peptides on the nasal absorption of insulin. J. Control. Release, 133, 103-108.
22. Auguste, D.T., Furman, K., Wong, A. et al. (2008) Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J. Control. Release, 130, 266-274.
23. Torchilin, V. (2008) Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. doi: 10.1016/j.ejpb.2008.09.026
24. Lomas, H., Canton, I., MacNeil, S. et al. (2007) Biomimetic pH sensitive polymersomes for efficient DNA encapsulation and delivery. Adv. Mater., 19, 4238-4243.
25. Li, J. and Loh, X.J. (2008) Cyclodextrin-based supramolecular architechtures: synthsis, structures, and applications for drug and gene delivery. Adv. Drug Del. Rev., 60, 1000-1017.
26. Hu-Lieskovan, S., Heidel, J.D., Bartlett, D.W. et al. (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewings sarcoma. Cancer Res., 65, 8984-8992.
27. Foldvari, M. and Bagonluri, M. (2008) Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomed. Nanotechnol. Biol. Med., 4, 183-200.
28. Kim, T., Ou, M., Lee, M. and Kim, S.W. (2009) Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials, 30, 658-664.
29. Unciti-Broceta, A., Diezmann, F., Ou-Yang, C.Y. et al. (2009) Synthesis, penetrability and intracellular targeting of fluorescein-tagged peptoids and peptide-peptoid hybrids. Bioorg. Med. Chem., 17, 959-966.
30. Morishita, M., Kamei, N., Ehara, J. et al. (2007) A novel approach using functional peptides for efficient intestinal absorption of insulin. J. Control. Release, 118, 177-184.
31. Foged, C. and Nielsen, H.M. (2008) Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin. Drug Deliv., 5, 105-117.
32. Borges, O., Silva, M., de Sousa, A. et al. (2008) Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol., 8, 1773-1780.
33. Nordly, P., Madsen, H.B., Nielsen, H.M. and Foged, C. (2009) Status and future prospects of lipid-based particulate delivery systems and immunostimulators as vaccine adjuvants. Expert Opin. Drug Del., 6, 1-16.
34. Coucke, D., Schotsaert, M., Libert, C. et al. (2009) Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine, 27, 1279-1286.
35. van de Weert, M. and Moeller, E.H. (2008) Immunogenicity of Biopharmaceuticals, Springer, New York, ISBN: 978-0-378-75840-4.
36. Schellekens, H. and Casadevall, N. (2004) Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol., 251, II/4-II/9.
37. Moghimi, S.M., Hunter, A.C. and Murray, J.C. (2005) Nanomedicine: current status and future prospects. FASEB J., 19, 311-330.
38. Wu, T.-L. and Ertl, H.C.J. (2009) Immune barriers to successful gene therapy. Trends Mol. Med., 15, 32-39.